Consensus Dr. Reddy's Laboratories Limited

Equities

DRREDDY

INE089A01031

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 05:24:00 2026-01-19 am EST			5-day change	1st Jan Change
1,166.45 ^INR	-0.77%		-3.56%	-8.23%

Jan. 16	Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Up Over 2% for Week	MT
Jan. 14	Dr. Reddy's Laboratories Ltd. Announces the Launch of Over-The-Counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%	CI

Evolution of the Average Target: Dr. Reddy's Laboratories Limited

Evolution of the Target Price: Dr. Reddy's Laboratories Limited

Changes in Analyst Recommendations: Dr. Reddy's Laboratories Limited

dbf7b544fc727f55b.UHabnkQQkkgiTSKVH87nLBTsdNozCUiPLz4jE62sej0.CgGu1wBh5R9mN3D7UZvVekeDA5xsfjHiRAZwTODZCX4hW87bKljUeFgDSQ~22a479c4f526c03d309ab97f835eb02d

Analysts' recommendations: Dr. Reddy's Laboratories Limited

25-10-30	Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,580 From INR1,650, Keeps at Buy	MT
25-10-27	Choice Equity Upgrades Dr. Reddy's Laboratories to Add from Reduce; Price Target is INR1,380	MT
25-10-27	Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,650 From INR1,660, Keeps at Buy	MT
25-10-27	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,130 From INR1,100, Keeps at Underperform	MT
25-10-13	BNP Paribas Exane Initiates Dr. Reddy's Laboratories at Neutral With $13.18 Price Target	MT
25-07-25	Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,660 From INR1,575, Keeps at Buy	MT
25-07-24	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,100 From INR1,010, Keeps at Underperform	MT
25-05-12	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,010 from INR1,170, Keeps at Underperform	MT
25-01-27	Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,575 From INR1,500, Keeps at Buy	MT
25-01-24	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,170 From INR1,210, Keeps at Underperform	MT
24-12-20	Nomura Upgrades Dr. Reddy's Laboratories to Buy From Neutral, Cuts Price Target to 1,500 Indian Rupees From 6,499 Indian Rupees	MT
24-11-06	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,130 From INR1,120, Keeps at Underperform	MT
24-07-29	Dr. Reddy's Rituximab Biosimilar Recommended for Launch by EMA Committee	MT
24-07-29	Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR5,600 From INR5,010, Keeps at Underperform	MT
24-05-08	Jefferies Adjusts Dr. Reddy’s Laboratories’ Price Target to INR5,010 From INR5,040, Keeps at Underperform	MT
24-01-29	Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $80 From $75, Keeps Overweight Rating	MT
23-10-30	Jefferies Adjusts Dr. Reddy’s Laboratories’ Price Target to INR6,250 From INR6,330, Keeps at Buy	MT
23-07-27	Jefferies Adjusts Dr. Reddy Laboratories’ to INR6,300 From INR5,600, Keeps at Buy	MT
23-06-01	Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $70 From $67, Maintains Overweight Rating	MT
23-01-30	Nomura Adjusts Dr Reddy's Laboratories' Price Target to INR5,161 From INR5,552, Keeps at Buy	MT
22-10-25	Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $66 From $69, Reiterates Overweight Rating	MT
22-09-12	Barclays Adjusts Dr. Reddy's Laboratories' Price Target to $69 from $68, Maintains Overweight Rating	MT
22-07-25	Barclays Lowers Dr. Reddy's Laboratories' Price Target to $68 From $70, Maintains Overweight Rating	MT
22-01-31	Nomura Adjusts Dr. Reddy's Laboratories’ Price Target to 5,552 Indian Rupees From 5,856 Indian Rupees, Keeps at Buy	MT
21-11-01	Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $80 From $78, Maintains Overweight Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	DR. REDDY'S LABORATORIES LIMITED					+10.25%
	ELI LILLY AND COMPANY					+6.97%
	JOHNSON & JOHNSON					-3.05%
	ABBVIE INC.					+14.32%
	ROCHE HOLDING AG					-1.9%
	ASTRAZENECA PLC					+8.47%
	NOVARTIS AG					-3.4%
	MERCK & CO., INC.					+4.27%
	NOVO NORDISK A/S					+3.11%
	AMGEN INC.					+0.36%
	Average					+3.94%
	Weighted average by Cap.					+3.79%